The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the prognostic value of p85 protein expression in HER2-positive and HER2-negative patients with advanced breast cancer treated with trastuzumab.
Kitty Pavlakis
No relevant relationships to disclose
Anna Koumarianou
No relevant relationships to disclose
Mattheos Bobos
No relevant relationships to disclose
Anna Batistatou
No relevant relationships to disclose
Vassiliki Kotoula
No relevant relationships to disclose
Anastasia G Eleftheraki
No relevant relationships to disclose
Anastasios Stofas
No relevant relationships to disclose
Eleni Timotheadou
No relevant relationships to disclose
George E. Pentheroudakis
No relevant relationships to disclose
Amanda Psyrri
No relevant relationships to disclose
Angelos Koutras
No relevant relationships to disclose
Dimitrios G. Pectasides
No relevant relationships to disclose
Pavlos Papakostas
No relevant relationships to disclose
Evangelia Razis
No relevant relationships to disclose
Konstantine T. Kalogeras
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose
Christos Christodoulou
No relevant relationships to disclose